Researchers have for the first time succeeded in converting skin cells into pluripotent stem cells by activating the cell's own genes.
Our bodies consist of many different kinds of cells, each with their own role, according to the study published in the journal Nature Communications.
Japanese scientist Shinya Yamanaka made the Nobel Prize discoverey in 2012 that cells from adult skin can be converted to cells typical of early embryos, so-called induced pluripotent stem cells (iPSC). This process is called reprogramming.
Up till now, reprogramming has only been possible by introducing the critical genes for the conversion, called Yamanaka factors, artificially into skin cells where they are not normally active at all.
Researchers from the University of Helsinki in Finland and King's College London in the UK have for the first time succeeded in converting skin cells into pluripotent stem cells by activating the cell's own genes.
This was achieved by using gene editing technology - called CRISPRa - that can be directed to activate genes. The method utilizes a blunted version of the Cas9 'gene scissors' that does not cut DNA and can therefore be used to activate gene expression without mutating the genome.
"CRISPR/Cas9 can be used to activate genes. This is an attractive possibility for cellular reprogramming because multiple genes can be targeted at the same time," said Timo Otonkoski, a professor at the University of Helsinki.
"Reprogramming based on activation of endogenous genes rather than overexpression of transgenes is also theoretically a more physiological way of controlling cell fate and may result in more normal cells.
"In this study, we show that it is possible to engineer a CRISPR activator system that allows robust reprogramming of iPSC," said Otonkoski.
An important key for the success was also activating a critical genetic element that was earlier found to regulate the earliest steps of human embryo development after fertilisation, researchers said.
"Using this technology, pluripotent stem cells were obtained that resembled very closely typical early embryonal cells," said Juha Kere from Karolinska Institutet and King's College London.
The discovery also suggests that it might be possible to improve many other reprogramming tasks by addressing genetic elements typical of the intended target cell type.
"The technology may find practical use in bio banking and many other tissue technology applications," said PhD student Jere Weltner.
"In addition, the study opens up new insights into the mechanisms controlling early embryonic gene activation," said Weltner.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
